CITISINA: Profilo di tollerabilità, tossicologia clinica e identità  fitoterapica

Linda Daffini

doi:10.3280/mis74-2026oa23196

Rassegna Clinica del Tabagismo

N. 74 (2026)

CITISINA: Profilo di tollerabilità, tossicologia clinica e identità fitoterapica

Linda Daffini^▸^▾

SCARICA QUI IL PDF

DOI: https://doi.org/10.3280/mis74-2026oa23196
Inviata: 3 luglio 2026
Pubblicato: 27-07-2026

Riferimenti bibliografici

Giulietti F., Filipponi A., Rosettani G., Giordano P., Iacoacci C., Spannella F., & Sarzani R. (2020). Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev., Oct, 27(5): 349-362. Doi: 10.1007/s40292-020-00396-9.
Jeong S.H., Sheridan J., Bullen C., Newcombe D., Walker N., & Tingle M. (2019). Ascending single dose pharmacokinetics of cytisine in healthy adult smokers. Xenobiotica, Nov, 49(11): 1332-1337. Doi: 10.1080/00498254.2018.1557760.
Majo García R., Espinosa Villoria M.G., Fernández-Martínez M.N., Díaz Madero A., Pérez Martín M.I., & Fernández-García D. (2025). Evidence Update on the Efficacy of Cytisinicline by Treatment Regimen: A Rapid Review. Open Respir Arch., Jul 23, 7(3), 100472. Doi: 10.1016/j.opresp.2025.100472.
Mitchell R.G. (1951). Laburnum poisoning in children; report on ten cases. Lancet, Jul 14, 2(6672): 57-8. Doi: 10.1016/s0140-6736(51)91315-3.
Prochaska J., Rubinstein M., Perdok R., Blumenstein B., & Jacobs C. (2026). Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. Thorax, Jan 15, 81(2): 164-169. Doi: 10.1136/thorax-2025-223880.
Puljevic´ C., Stjepanovic´ D., Meciar I., Kang H., Chan G., Morphett K., Bendotti H., Kunwar G., & Gartner C. (2024). Systematic review and meta-analyses of cytisine to support tobacco cessation. Addiction, Oct, 119(10): 1713-1725. Doi: 10.1111/add.16592.
Rigotti N.A., Benowitz N.L., Prochaska J., Leischow S., Nides M., Blumenstein B., Clarke A., Cain D., & Jacobs C. (2023). Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA, Jul 11, 330(2): 152-160. Doi: 10.1001/jama.2023.10042.
S´wia˛tkowski W., Budzyn´ska B., Macia˛g M., S´wia˛tkowska A., Tylz˙anowski P., Rahnama-Hezavah M., Stachurski P., & Chałas R. (2023). Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model. Int J Mol Sci., Jul 28, 24(15), 12094. doi: 10.3390/ijms241512094.
Tedesco E., Ceccato S., Torazzi A., Santin L., Losso L., Bottardi A., Casari R., Melchiori S., Secchettin E., Ferrero V., Arzenton E., Marini P., Lugoboni F., & Chiamulera C. (2025), Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study. Intern Emerg Med., Sep, 20(6): 1987. Doi: 10.1007/s11739-025-04067-2.
Tutka P., Vinnikov D., Courtney R.J., & Benowitz N.L. (2019). Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction, Nov, 114(11): 1951-1969. Doi: 10.1111/add.14721.
Walker N., Bullen C., Barnes J., McRobbie H., Tutka P., Raw M., Etter J.F., Siddiqi K., Courtney R.J., Castaldelli-Maia J.M., Selby P., Sheridan J., & Rigotti N.A. (2016). Getting cytisine licensed for use worldwide: a call to action. Addiction, Nov, 111(11): 1895-1898. Doi: 10.1111/add.13464.
West R., Zatonski W., Cedzynska M., Lewandowska D., Pazik J., Aveyard P., & Stapleton J. (2011). Placebocontrolled trial of cytisine for smoking cessation. N Engl J Med., Sep 29, 365(13): 1193-200. Doi: 10.1056/NEJMoa1102035.

Come citare

Daffini, L. (2026). CITISINA: Profilo di tollerabilità, tossicologia clinica e identità fitoterapica. Mission - Open Access, (74). https://doi.org/10.3280/mis74-2026oa23196

[1] Giulietti F., Filipponi A., Rosettani G., Giordano P., Iacoacci C., Spannella F., & Sarzani R. (2020). Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev., Oct, 27(5): 349-362. Doi: 10.1007/s40292-020-00396-9.

[2] Jeong S.H., Sheridan J., Bullen C., Newcombe D., Walker N., & Tingle M. (2019). Ascending single dose pharmacokinetics of cytisine in healthy adult smokers. Xenobiotica, Nov, 49(11): 1332-1337. Doi: 10.1080/00498254.2018.1557760.

[3] Majo García R., Espinosa Villoria M.G., Fernández-Martínez M.N., Díaz Madero A., Pérez Martín M.I., & Fernández-García D. (2025). Evidence Update on the Efficacy of Cytisinicline by Treatment Regimen: A Rapid Review. Open Respir Arch., Jul 23, 7(3), 100472. Doi: 10.1016/j.opresp.2025.100472.

[4] Mitchell R.G. (1951). Laburnum poisoning in children; report on ten cases. Lancet, Jul 14, 2(6672): 57-8. Doi: 10.1016/s0140-6736(51)91315-3.

[5] Prochaska J., Rubinstein M., Perdok R., Blumenstein B., & Jacobs C. (2026). Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. Thorax, Jan 15, 81(2): 164-169. Doi: 10.1136/thorax-2025-223880.

[6] Puljevic´ C., Stjepanovic´ D., Meciar I., Kang H., Chan G., Morphett K., Bendotti H., Kunwar G., & Gartner C. (2024). Systematic review and meta-analyses of cytisine to support tobacco cessation. Addiction, Oct, 119(10): 1713-1725. Doi: 10.1111/add.16592.

[7] Rigotti N.A., Benowitz N.L., Prochaska J., Leischow S., Nides M., Blumenstein B., Clarke A., Cain D., & Jacobs C. (2023). Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA, Jul 11, 330(2): 152-160. Doi: 10.1001/jama.2023.10042.

[8] S´wia˛tkowski W., Budzyn´ska B., Macia˛g M., S´wia˛tkowska A., Tylz˙anowski P., Rahnama-Hezavah M., Stachurski P., & Chałas R. (2023). Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model. Int J Mol Sci., Jul 28, 24(15), 12094. doi: 10.3390/ijms241512094.

[9] Tedesco E., Ceccato S., Torazzi A., Santin L., Losso L., Bottardi A., Casari R., Melchiori S., Secchettin E., Ferrero V., Arzenton E., Marini P., Lugoboni F., & Chiamulera C. (2025), Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study. Intern Emerg Med., Sep, 20(6): 1987. Doi: 10.1007/s11739-025-04067-2.

[10] Tutka P., Vinnikov D., Courtney R.J., & Benowitz N.L. (2019). Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction, Nov, 114(11): 1951-1969. Doi: 10.1111/add.14721.

[11] Walker N., Bullen C., Barnes J., McRobbie H., Tutka P., Raw M., Etter J.F., Siddiqi K., Courtney R.J., Castaldelli-Maia J.M., Selby P., Sheridan J., & Rigotti N.A. (2016). Getting cytisine licensed for use worldwide: a call to action. Addiction, Nov, 111(11): 1895-1898. Doi: 10.1111/add.13464.

[12] West R., Zatonski W., Cedzynska M., Lewandowska D., Pazik J., Aveyard P., & Stapleton J. (2011). Placebocontrolled trial of cytisine for smoking cessation. N Engl J Med., Sep 29, 365(13): 1193-200. Doi: 10.1056/NEJMoa1102035.